Bayer Aktiengesellschaft (BAYNd)
FRA • Healthcare
October 9, 2026 at 15:30 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every €100 in revenue, Bayer Aktiengesellschaft keeps €2 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Bayer’s adjusted EPS topped expectations while revenue came in line with consensus in the second fiscal quarter of 2026, reported August 4, as revenue rose 1.2% to roughly €10.9 billion (up from about €10.7 billion a year ago). Adjusted EPS of €0.94 topped the €0.76 estimate, +23%, while revenue of €10.872 billion was in line with the €10.728 billion consensus (+1.3%). Profitability included gross profit of about €6.3 billion, with gross margin at roughly 58%, and operating income of about €827 million for an operating margin near 8%. Bayer generated operating cash flow of roughly €690 million during the quarter and paid about €112 million in dividends. For the next period, consensus calls for EPS of €0.50 on revenue of €9.877 billion.
Next report — what to expect
Bayer AG (BAYN.DE) is set to report earnings on November 3, 2026. Wall Street is looking for consensus EPS of EUR 0.417 on consensus revenue of EUR 9.89 billion; as trailing context, revenue rose +1.2% year over year last quarter. Bayer has beaten EPS in 7 of 8 most recent quarters.
About Bayer Aktiengesellschaft
Bayer AG trades on XETRA as BAYN.DE and operates across branded medicines, consumer health products, and agricultural inputs, placing it in healthcare and the broad Drug Manufacturers - General group. Its business spans pharmaceuticals, self-care, and crop science, and it generated EUR 45.6 billion of revenue in FY2025.
Today's Snapshot
BAYNd closed 2.8% higher at 43.78, in line with a firmer sector. Shares changed hands at about a third of its usual level. Bayer is seeking broader use of Kerendia, its chronic kidney disease drug.
Trading Volume
Below 10d avg (2.3M)
818.8K
vs S&P 500 Today
Outperforming Market
+2.54%
Updated: October 9, 2026 at 14:07 UTC
BAYNd Headlines
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$42.37 - $47.21Sell
- RSI (14)34.64Neutral
- Stochastic %K (14, 3, 3)6.27Buy
- MACD Level (12, 26)-1.37Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.